Last reviewed · How we verify
DWC202304
DWC202304 is a therapeutic agent that targets a specific molecular pathway.
DWC202304 is a therapeutic agent that targets a specific molecular pathway. Used for Phase 3 clinical trials are ongoing for DWC202304..
At a glance
| Generic name | DWC202304 |
|---|---|
| Also known as | Orafang Tab |
| Sponsor | Daewoong Pharmaceutical Co. LTD. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
However, the exact mechanism of action is not well-documented at this time.
Approved indications
- Phase 3 clinical trials are ongoing for DWC202304.
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DWC202304 CI brief — competitive landscape report
- DWC202304 updates RSS · CI watch RSS
- Daewoong Pharmaceutical Co. LTD. portfolio CI